AVNR has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
GuruFocus Financial Strength Rank measures how strong a companys financial situation is. It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank
|Louis Moore Bacon 100,000 sh (New)|
Chuck Royce 1,289,100 sh (New)
Paul Tudor Jones 127,470 sh (New)
Jim Simons 58,014 sh (New)
Leon Cooperman 100,000 sh (New)
Steven Cohen 498,500 sh (+147.03%)
|Mario Gabelli 493,524 sh (New)|
Jim Simons 884,514 sh (+1424.66%)
Louis Moore Bacon 150,000 sh (+50.00%)
|Louis Moore Bacon 150,000 sh (unchged)||Leon Cooperman Sold Out|
Steven Cohen Sold Out
Chuck Royce 405,100 sh (-68.57%)
Paul Tudor Jones 22,895 sh (-82.04%)
(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
|EPS without NRI($)||-4.56||-3.55|
|Industry:||Drug Manufacturers » Drug Manufacturers - Specialty & Generic|
|Compare:||TKPYY, TEVA, AGN, FRX, MRX » details|
|Traded in other countries:||AV2B.Germany,|
|Avanir Pharmaceuticals was incorporated in California in August 1988 and was reincorporated in Delaware in March 2009. The Company is a biopharmaceutical company focused on acquiring, developing and commercializing novel therapeutic products for the treatment of central nervous system disorders. The Company commenced promotion of NUEDEXTA in the United States in February 2011. The Company is also studying AVP-923 for use in different types of neuropathic pain. NUEDEXTA is the first and only FDA-approved treatment for pseudobulbar affect. NUEDEXTA is an combination of two components: dextromethorphan hydrobromide, the ingredient that is harmacologically active in the central nervous system, and quinidine sulfate, a metabolic inhibitor enabling dextromethorphan to reach therapeutic plasma concentrations. The Company currently markets NUEDEXTA to approximately 10,000 physicians and other healthcare providers who specialize in psychiatry, neurology or geriatric medicine and practice in outpatient or long-term care settings. NUEDEXTA may face competition from several products: Antidepressants, including Prozac, Celexa, Zoloft, Paxil, Elavil and Pamelor and others; Atypical antipsychotic agents, including Zyprexa, Risperdal, Seroquel, Abilify, Geodon and others; and Miscellaneous agents, including Symmetrel, Lithium and others. The Company is subject to regulation under the Occupational Safety and Health Act, the Environmental Protection Act, the Toxic Substance Control Act, the Export Control Act and other present and future laws of general application.|
|Gabelli's Q4 Picks Include Acquisition Targets Feb 06 2015|
|A Look at Leon Cooperman's Most Performing Recent Buys Jan 30 2015|
|Weekly CEO Sells Highlight: Danaher Corporation, Orbitz Worldwide Inc., 3D Systems Corporation and A May 20 2013|
|Weekly CEO Sells Highlight: Universal Insurance Holdings Inc, Avanir Pharmaceuticals Inc, Bel Fuse I Jun 30 2012|
|Options V: Short-Term Strategy – Earning Money on Volatility Oct 19 2011|
|Avanir Pharmaceuticals Reports Operating Results (10-Q) Feb 07 2011|
|Avanir Pharmaceuticals Reports Operating Results (10-K) Dec 08 2010|
|Avanir Pharmaceuticals (AVNR) President and CEO Keith Katkin sells 195,300 Shares Dec 03 2010|
|Weekly CEO Sells Highlights: MAC, GNET, ASIA, and AVNR Sep 05 2010|
|Avanir Pharmaceuticals (AVNR) President and CEO Keith Katkin sells 102,874 Shares Sep 02 2010|